Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 8/20 | 0.73 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406370 | 0.84 | PARK7 (0.76) | CHRM5PARK7CA12CA1CA2 | |
| SCHEMBL578232 | 0.84 | PARK7 (0.76) | CHRM5PARK7CA12CA1CA2 | |
| SCHEMBL5659656 | 0.83 | ACHE (0.66) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL18955277 | 0.83 | PARK7 (0.63) | CHRM5PARK7CA12CA1CA2 | |
| SCHEMBL9904848 | 0.83 | ALDH3A1 (0.72) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL5659567 | 0.81 | ALDH1A1 (0.71) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL4609842 | 0.80 | CES1 (0.66) | CHRM5ALDH1A1ALDH2ALDH3A1TP53 | |
| SCHEMBL5429853 | 0.78 | ALDH3A1 (0.54) | CHRM5PARK7CA12CA1CA2 | |
| SCHEMBL18954802 | 0.78 | CHRM5 (0.60) | CHRM5CA12CA1CA2CA9 | |
| SCHEMBL5429061 | 0.77 | CHRM5 (0.72) | CHRM5PARK7CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2750508-A1 | THERAPEUTIC COMPOUNDS AND METHODS | Wayne State University (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | CHRM5 4705/4885PARK7 1869/4885CA12 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.